Latest filing published 03 Oct 2017 for Ernexa Therapeutics Inc..
Insider track record
Closed purchases
Based on 11 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -18.2%Entry US$127,500.00 · Close at T+365 US$104,250.00
- -16.8%Entry US$180,000.00 · Close at T+365 US$149,700.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Paul Yanover: trading record in brief
All filings by Paul Yanover on record concern Ernexa Therapeutics Inc. We count 14 filings; the first trade dates from 14 December 2012 and the latest from 29 September 2017.
No open-market sale appears; the market trades are 11 purchases worth €19k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants.
The median purchase comes to €703. 9 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 11 purchases with a full 90-day history, the hit rate stands at 18% and the median 90-day move at -35.2%. These figures describe past trades and do not predict future prices.
The latest filing, published on 3 October 2017, reports a share grant in Ernexa Therapeutics Inc. The last insider purchase was made public on 26 May 2016, 3,819 days ago. Most trades are made public on the day they happen. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Paul Yanover
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 612 shares0Common StockSEC:0001493152-17-011199:0
- 551 shares0Common StockSEC:0001493152-17-007511:0
- 32,468 shares@ US$0.169850.6% of flowCommon StockSEC:0001493152-16-010361:0Canonical exit: 24 Aug 2016 (T+90)
- 15,000 shares@ US$0.165922.8% of flowCommon StockSEC:0001493152-16-010361:1Canonical exit: 24 Aug 2016 (T+90)
- 8,497 shares@ US$0.169713.2% of flowCommon StockSEC:0001493152-16-010361:2Canonical exit: 24 Aug 2016 (T+90)
- 5,000 shares@ US$0.15737.2% of flowCommon StockSEC:0001493152-16-010361:3Canonical exit: 24 Aug 2016 (T+90)
- 1,869 shares@ US$0.16492.8% of flowCommon StockSEC:0001493152-16-010361:4Canonical exit: 24 Aug 2016 (T+90)
- 900 shares@ US$0.1661.4% of flowCommon StockSEC:0001493152-16-010361:5Canonical exit: 24 Aug 2016 (T+90)
- 700 shares@ US$0.1681.1% of flowCommon StockSEC:0001493152-16-010361:6Canonical exit: 24 Aug 2016 (T+90)
- 500 shares@ US$0.1650.8% of flowCommon StockSEC:0001493152-16-010361:7Canonical exit: 24 Aug 2016 (T+90)
- 66 shares@ US$0.150.1% of flowCommon StockSEC:0001493152-16-010361:8Canonical exit: 24 Aug 2016 (T+90)
- 7,900 shares@ US$0.2467Common StockSEC:0001019687-15-002463:0Canonical exit: 17 Sept 2015 (T+90)
- 32,100 shares@ US$0.2497Common StockSEC:0001019687-15-002463:1Canonical exit: 17 Sept 2015 (T+90)
- 100,000 shares0Common StockSEC:0001019687-12-004569:0
14 of 14 declarations
